$PTGX News

Protagonist Therapeutics: The Opt-Out That Turned A Biotech Into A Royalty Compounder

TD Cowen Maintains Buy on Protagonist Therapeutics, Raises Price Target to $160

A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday

Protagonist Therapeutics (NASDAQ:PTGX): Strong Growth Meets Constructive Technical Setup

Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should Know

Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth Today

UBS Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $184

Leerink Partners Assumes Protagonist Therapeutics at Outperform, Raises Price Target to $190

Protagonist Therapeutics (NASDAQ:PTGX): High Growth Momentum Meets Breakout Setup

Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth Today

Protagonist Therapeutics (NASDAQ:PTGX) Combines Strong Growth With a High-Quality Technical Setup

Protagonist Therapeutics (NASDAQ:PTGX) Combines High Growth Momentum With a Breakout Setup

Protagonist Therapeutics, Inc. (PTGX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Protagonist Therapeutics Announces $300 Million Share Repurchase Program

Protagonist Therapeutics Announces $300M Buyback Plan

Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status

Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026

Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $180

BMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $190

Protagonist Therapeutics (PTGX) Could Be 63% Below Fair Value After Investor Update Call